We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.49B
AUM Growth
-$101M
Cap. Flow
+$10.3M
Cap. Flow %
0.69%
Top 10 Hldgs %
30.22%
Holding
143
New
5
Increased
56
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$24.2M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$11.2M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.9M
5
MRK icon
Merck
MRK
+$9.97M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.8M
2
HCA icon
HCA Healthcare
HCA
+$32.5M
3
MCK icon
McKesson
MCK
+$13.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.83M
5
GI
EndoChoice Holdings, Inc.
GI
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.35%
2 Financials 4.56%
3 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVTA
51
DELISTED
Invitae Corporation
NVTA
$9.53M 0.64%
1,200,000
+310,000
+35% +$2.32M
EVHC
52
DELISTED
Envision Healthcare Holdings Inc
EVHC
$9.18M 0.61%
145,000
+47,806
+49% +$3.12M
BOLD
53
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.86M 0.59%
485,000
– –
MRUS
54
DELISTED
Merus
MRUS
$8.44M 0.57%
400,000
+17,000
+4% +$290K
CLSD
55
DELISTED
Clearside Biomedical
CLSD
$8.36M 0.56%
62,333
-19,334
-24% -$4.85M
FPRX
56
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$8.22M 0.55%
164,000
-2,250
-1% -$118K
PRTK
57
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.09M 0.54%
525,500
+23,000
+5% +$299K
ONC
58
BeOne Medicines Ltd
ONC
$39.4B
$8.04M 0.54%
265,000
+40,000
+18% +$1.26M
REGN icon
59
Regeneron Pharmaceuticals
REGN
$80.8B
$7.16M 0.48%
19,500
+2,500
+15% +$951K
LGND icon
60
Ligand Pharmaceuticals
LGND
$6.36B
$7.11M 0.48%
112,210
+8,015
+8% +$506K
ALKS icon
61
Alkermes
ALKS
$8.25B
$6.95M 0.46%
125,000
-58,027
-32% -$3.1M
EPZM
62
DELISTED
Epizyme, Inc
EPZM
$6.9M 0.46%
570,000
-72,500
-11% -$757K
AVXS
63
DELISTED
AveXis, Inc. Common Stock
AVXS
$6.68M 0.45%
140,000
– –
VRTX icon
64
Vertex Pharmaceuticals
VRTX
$126B
$6.61M 0.44%
89,750
– –
ATHN
65
DELISTED
Athenahealth, Inc.
ATHN
$6.6M 0.44%
62,750
+17,000
+37% +$1.83M
ASND icon
66
Ascendis Pharma A/S
ASND
$16.8B
$6.58M 0.44%
325,000
+25,000
+8% +$499K
CRVS icon
67
Corvus Pharmaceuticals
CRVS
$1.17B
$6.43M 0.43%
450,000
– –
INSM icon
68
Insmed
INSM
$28.6B
$6.19M 0.41%
468,000
-35,000
-7% -$477K
SRGA
69
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$6.04M 0.4%
62,000
– –
EXAS
70
DELISTED
Exact Sciences
EXAS
$6.02M 0.4%
450,900
+15,900
+4% +$257K
AIMT
71
DELISTED
Aimmune Therapeutics
AIMT
$5.99M 0.4%
293,000
– –
ACHN
72
DELISTED
Achillion Pharmaceuticals
ACHN
$5.68M 0.38%
1,375,000
+59,000
+4% +$314K
KA
73
DELISTED
Kineta, Inc. Common Stock
KA
$5.52M 0.37%
3,214
– –
CO
74
DELISTED
Global Cord Blood Corporation
CO
$5.39M 0.36%
880,000
– –
SRPT icon
75
Sarepta Therapeutics
SRPT
$1.77B
$5.26M 0.35%
191,900
+18,900
+11% +$759K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rock Springs Capital Management held 143 positions worth $1.49B, down 6.3% from $1.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2016 filing shows 5 new, 56 increased, 18 reduced and 10 closed positions. Its largest new stake was UnitedHealth: 165,000 shares worth $26.4M. The largest sale was Pfizer, an estimated $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2016 buy was UnitedHealth: 165,000 shares worth $26.4M.
  • Rock Springs Capital Management added most to Alexion Pharmaceuticals in Q4 2016, an estimated $24.2M increase.
  • Rock Springs Capital Management's biggest Q4 2016 reduction was Gilead Sciences, cutting an estimated $5.02M.
  • Rock Springs Capital Management fully exited Pfizer in Q4 2016, selling an estimated $35.8M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $1.49B portfolio in Q4 2016.
  • Rock Springs Capital Management opened 5 new positions and closed 10 in Q4 2016.
  • Rock Springs Capital Management's portfolio value fell 6.3% quarter-over-quarter to $1.49B.

Based on Rock Springs Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.